COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced it has received approval from Health Canada to initiate a pediatric expanded access treatment program for Prochymal, making the investigational stem cell product more readily available to children with life-threatening Graft vs. Host Disease (GvHD). Earlier this year the U.S. Food and Drug Administration became the first regulatory agency to take this action, making Prochymal available to children in the United States.
